- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Phase 1 in Singapore
Total 18 results
-
Nanyang Technological UniversityNational Gallery SingaporeEnrolling by invitationCompassion | Mental Health Wellness 1 | Self CareSingapore
-
Singapore Eye Research InstituteUnknownLeukemia (Both ALL and AML) | MDS-EB-1Singapore
-
National University Health System, SingaporeCompletedThymic Carcinoid | Multiple Endocrine Neoplasia Type 1 (MEN-1)Singapore
-
Yale-NUS CollegeCompletedMental Health Wellness 1 | Mental Health Issue | Social Media Addiction | Internet Addiction | Mental Health Wellness 2Singapore
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1Singapore
-
KK Women's and Children's HospitalLien FoundationRecruitingMental Health Wellness 1 | Metabolic Disease | Maternal Obesity | Lifestyle Risk ReductionSingapore
-
TakedaActive, not recruitingMyeloid Leukemia, Chronic, Chronic PhaseUnited States, Spain, Taiwan, Australia, Canada, Russian Federation, Sweden, Switzerland, Germany, United Kingdom, Poland, Korea, Republic of, Argentina, Hong Kong, Singapore, Italy, Chile, Czechia, Denmark, France, Portugal
-
Bristol-Myers SquibbCompletedChronic Myelogenous LeukemiaNetherlands, United States, Italy, Argentina, Brazil, Canada, Germany, Peru, Singapore, Taiwan, United Kingdom, France, Korea, Republic of, Philippines, Sweden, Thailand, Finland, Australia, Israel, Belgium, Denmark, Norway, Switzer...
-
Bristol-Myers SquibbActive, not recruitingLeukemiaFrance, India, United States, Canada, Spain, Italy, Mexico, South Africa, United Kingdom, Korea, Republic of, Russian Federation, Australia, Argentina, Germany, Brazil, Netherlands, Romania, Singapore
-
Bristol-Myers SquibbCompletedMyeloid Leukemia, Chronic, Chronic-PhaseUnited States, Australia, France, Germany, Italy, Korea, Republic of, Sweden, Taiwan, Spain, Austria, Denmark, Belgium, Canada, Ireland, Switzerland, Netherlands, Peru, United Kingdom, South Africa, Argentina, Philippines, Singapore, Russian Federation and more
-
EDDC (Experimental Drug Development Centre), A*STAR...Chiltern International Inc.WithdrawnPh+ Acute Lymphoblastic Leukemia (Ph+ALL) | Ph- Acute Lymphoblastic Leukemia (Ph-ALL) | Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+) | Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+)United States, Singapore
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1Turkey, Egypt, Philippines, United Arab Emirates, Bangladesh, Colombia, Singapore, South Africa
-
Singapore General HospitalCompletedAngioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Peripheral T-cell Lymphoma (Not Otherwise Specified) | Extranodal NK/T-cell Lymphoma Nasal Type | Enteropathy- Type T-cell Lymphoma | Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative) | Relapsed ALCL (ALK-1 Positive) Post...Singapore, Malaysia, Korea, Republic of
-
PfizerCompletedLeukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) PositiveFrance, United States, Canada, Spain, Czechia, Singapore, Thailand, Denmark, Norway, Korea, Republic of, Finland, Hungary, Sweden, Netherlands, Italy, Germany, Ukraine, South Africa, Taiwan, Australia, Belgium, Israel, Mexico, Poland, S... and more
-
Bristol-Myers SquibbCompletedLeukemia, Lymphoblastic, Acute, Philadelphia-Positive | Myeloid Leukemia, Chronic, Accelerated PhaseAustralia, Canada, France, Germany, Italy, Korea, Republic of, Taiwan, Thailand, United States, Spain, Austria, Denmark, Belgium, Sweden, Switzerland, Netherlands, Peru, South Africa, Philippines, Singapore, Russian Federation, Br... and more
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States, Canada, Singapore
-
Bristol-Myers SquibbCompletedChronic Myeloid Leukemia | Blast CrisisNetherlands, United States, Italy, Austria, Canada, France, Germany, Singapore, Taiwan, United Kingdom, Australia, Korea, Republic of, Philippines, Sweden, Finland, Israel, Belgium, Denmark, Norway, Switzerland
-
Novartis PharmaceuticalsRecruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationItaly, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom